Promote the development of vaccines with high development priorities and accelerate discussions on NIP vaccination

As for vaccines with high development priority, the government has requesed companies to develop them, and there were many remarks from members of the council that priority should be given to discussions on routine vaccination ahead of other vaccines, and there was support to proceed to the next discussion without objection on this point. EFPIA member companies include pediatric combination vaccines, Herpes Zoster vaccines, high-dose Influenza vaccines, and RS virus vaccines


  • Improving the predictability of NIP is being incorporated into the government's basic policy, and we will promote clear criteria for NIP vaccinations and the creation of a system that allows discussions on NIP vaccinations to begin even before vaccines are approved.